Table 1.
Applied radiotracers and organizational parameters of the included prospective clinical prostate cancer-related trials with PSMA-radioligands from the ClinicalTrials.gov registry (n = 104).
| Absolute (n) | Relative (%) * | |
|---|---|---|
| Applied PSMA radioligand | ||
| [68Ga]Ga-PSMA-11 | 33 | 32 |
| [18F]DCFPyL | 25 | 24 |
| [177Lu]Lu-PSMA-617 | 10 | 10 |
| Other (e.g., [99mTc]Tc-MIP-1404, [18F]DCFBC, [18F]PSMA-1007) | 36 | 35 |
| Organization/Cooperation | ||
| Single-center/Multi-center | ||
| Single-center | 88 | 85 |
| Multi-center | 16 | 15 |
| National/International | ||
| National | 99 | 95 |
| International | 5 | 5 |
| Funding source ** | ||
| Industry | 31 | 30 |
| NIH | 20 | 19 |
| Other U.S. Federal agency | 1 | 1 |
| All others (individuals, universities, organizations) | 81 | 78 |
* Sum partly ≠ 100 due to rounding. ** More than one choice possible. Source: Own table based on the evaluation of the ClinicalTrials.gov dataset [30].